البلد: المملكة المتحدة
اللغة: الإنجليزية
المصدر: MHRA (Medicines & Healthcare Products Regulatory Agency)
Azathioprine
Strides Pharma UK Ltd
L04AX01
Azathioprine
50mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 08020100; GTIN: 5031676000181 5031676004202
Strides Pharma UK Ltd. Front & Back Printing. To be supplied in the folded size of 150 x 200mm Record Number: 304566 60 GSM Paper. Pack Insert 150 X 400 MM 1042986 -- 1 12.0 AZATHIOPRINE TABLETS - 50 MG BLACK Printing clarity to be clear & sharp. 1042190 PACKAGE LEAFLET: INFORMATION FOR THE USER AZATHIOPRINE TABLETS 50 MG READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. • Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Azathioprine Tablets are and what they are used for 2. What you need to know before you take Azathioprine Tablets 3. How to take Azathioprine Tablets 4. Possible side effects 5. How to store Azathioprine Tablets 6. Contents of the pack and other information 1. WHAT AZATHIOPRINE TABLETS ARE AND WHAT THEY ARE USED FOR Azathioprine Tablets contains the active substance azathioprine which belongs to a group of medicines called immunosuppressants. This means that they reduce the strength of your immune system. Azathioprine is used for protection against organ transplant rejection. It can also be used to treat various conditions in which the usual treatment (with steroids) is not working properly, is causing problems or where steroids cannot be used. These conditions include hepatitis, rheumatoid arthritis, systemic lupus erythematosus (SLE), dermatomyositis and polymyositis (conditions which affect the muscles and skin), various blood and bleeding disorders and skin disorders. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE AZATHIOPRINE TABLETS DO NOT TAKE AZATHIOPRINE TABLETS IF YOU: • Are allergic to azathioprine, 6-mercaptop اقرأ الوثيقة كاملة
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Azathioprine Tablets 50 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each uncoated tablet contains azathioprine 50mg Excipient(s) with known effect Lactose monohydrate For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Pale yellow, biconvex tablets scored on one side and engraved with a logo mortar and pestle on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Azathioprine tablets are used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. Azathioprine tablets, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated to enhance the survival of organ transplants, such as renal transplants, cardiac transplants, and hepatic transplants. it also reduces the corticosteroid requirements of renal transplant recipients. Azathioprine tablets are indicated for the treatment of moderate to severe inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom corticosteroid therapy is required, in patients who cannot tolerate corticosteroid therapy, or in patients whose disease is refractory to other standard first line therapy. Azathioprine tablets, either alone or more usually in combination with corticosteroids and/or other medicinal products and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: • severe rheumatoid arthritis • systemic lupus erythematosus • dermatomyositis and polymyositis • auto-immune chronic active hepatitis • pemphigus vulgaris • polyarterit اقرأ الوثيقة كاملة